<DOC>
	<DOCNO>NCT02722343</DOCNO>
	<brief_summary>This single site study design describe measure efficacy oral versus vaginal dose TFV-based product , specifically emtricitabine/tenofovir disoproxil fumarate oral tablet ( Truvada ) v tenofovir intravaginal ring ( IVR ) .</brief_summary>
	<brief_title>Exploratory Pharmacodynamic Study Tenofovir-Based Products</brief_title>
	<detailed_description>This study compare investigational intravaginal ring contain tenofovir ( TFV ) FDA approve medication tablet form call Truvada® . It assess compare ability tablet intravaginal ring prevent HIV transmission ( human immunodeficiency virus , virus cause AIDS ) . The study enroll healthy , non-pregnant , HIV negative , premenopausal woman ( age 18-50 , regular menstrual cycle ) risk pregnancy . The enrollment goal 20 participant complete study . Participants assign use one study product : oral tablet intravaginal ring . Participants take oral tablet day 14 day wear intravaginal ring day night 14 days/nights . Blood , genital fluid sample genital tissue sample ( biopsy ) take two visit . These sample collection take place use assign study product . The sample test : 1 . Determine level drug blood genital tissue sample 2 . See sample take vagina cervix use study product , provide protection HIV laboratory 3 . Ensure laboratory test use measure HIV infection sample performs well use repeatedly . In addition study also evaluate return TFV ring see whether use instruct .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>General good health ( volunteer history per investigator judgment ) without clinically significant systemic disease ( include , limited significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , diabetes ) intact gastrointestinal tract , uterus cervix Currently regular menstrual cycle 2135 day participant record Willing abstain vaginal intercourse vaginal activity include use vaginal product ( tampon , spermicide , lubricant , douche ) study product : 48 hour Visit 2 six day Visit 2 48 hour Visit 3 six day Visit 4 Vaginal cervical anatomy , opinion investigator , lend easy genital tract sample collection Estimated calculate creatinine clearance ( eCcr ) least 60 mL/min History Pap smear followup consistent standard clinical practice outline study manual willing undergo Pap smear Visit 1 Protected pregnancy one following : sterilization either partner abstinence sex relationship condom combine contraceptive ( include oral , patch ) copper IUD Willing able comply protocol requirement include swallow tablet Willing give voluntary consent sign inform consent form History hysterectomy Currently pregnant within two calendar month last pregnancy outcome . Note : recently pregnant must least two spontaneous menses since pregnancy outcome Injection DepoProvera last 10 month use progestinonly base contraceptive ( include hormonal IUD ) Currently breastfeed plan breastfeed course study History sensitivity/allergy component study product , topical anesthetic , silver nitrate Monsel 's solution In last three month , diagnose treated STI , self report Positive test Trichomonas vaginalis , Neisseria gonorrhea , Chlamydia trachomatis , HIV , Hepatitis B surface antigen ( HBsAg ) Note : Women history genital herpes asymptomatic least three month may consider eligibility Chronic acute vulvar vaginal symptom ( pain , irritation , spotting/bleeding , discharge , etc . ) Known bleed disorder could lead prolonged continuous bleed biopsy Systemic use last two week anticipate use study follow : corticosteroid , antibiotic , anticoagulant drug know prolong bleed and/or clotting , antifungal , antiviral ( e.g. , acyclovir , valacyclovir , Viread® , Atripla® , Emtriva® , Complera® ) Current anticipate chronic use NSAIDS , Tylenol duration study Grade 2 high laboratory abnormality , per 2014 update Division AIDS , National Institute Allergy Infectious Disease ( DAIDS ) Table Grading Severity Adverse Events , clinically significant laboratory abnormality determine clinician Abnormal find laboratory physical examination social medical condition either volunteer , opinion investigator , would make participation study unsafe would complicate interpretation data Known current drug alcohol abuse could impact study compliance Participation investigational trial within last 30 day plan participation investigational trial study History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix within last 14 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>